On the 27th and 28th of January 2022, Consortium members gathered virtually for two days of presentations, demos, and discussion. There were a variety of sessions covering topics including how anti-TB potential compounds investigations are progressing in the preclinical and clinical phases, new experimental protocols, and capacity creation.
Two key updates were announced at the meeting:
- Centre d’Investigació del Medicament (CIM) – Sant Pau becomes a new partner in the consortium to participate in Phase I, First Time in Human (FTIH) activities. Read more about CIM – Sant Pau here
- The Scientific Advisory Board (SAB) has been set up with three renowned external experts to advise the project on scientific and technical development:
- Dr Gilla Kaplan, former Director of the Global Health Program Tuberculosis at the Bill and Melinda Gates Foundation.
- Dr Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy at The European Medicines Agency.
- Dr Herman Goossens, Professor of Microbiology at the University of Antwerp and Director of the Department of Clinical Pathology of the University Hospital, Antwerp.
Dr Gilla Kaplan, representative of the SAB at the Consortium Meeting, congratulated the group on the great strides made despite the troubles of the Covid-19 pandemic.
Gilla Kaplan (SAB member):
“There has been an enormous amount of progress seen in models, assays, and protocols.”
“This consortium is filling the gaps, catching up and establishing all the tools that are going to make it possible to come up with good regimens”
We thank you all for the strong contributions made and we are looking forward to meeting face-to-face soon!